A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Enrico Derenzini, Franck Morschhauser, Vincent Ribrag, Elizabeth Phillips, Hervé Ghesquieres, Hun Ju Lee, Borchmann Peter, Paul Jan Bröckelmann, Tae Min Kim, Katharine L. Lewis, Jakub Svoboda, Antonia Rodriguez Izquierdo, Won Seog Kim, Anna Sureda, Graham P. Collins, Kaitlyn Beyfuss, Cedric Dos Santos, Richard F. Olsson, Pier Luigi Zinzani
Institutions: European Institute of Oncology, Centre Hospitalier Universitaire de Lille, Institut Gustave Roussy, University of Manchester, The Christie NHS Foundation Trust, Hôpital Lyon Sud, The University of Texas MD Anderson Cancer Center, University Hospital Cologne, Seoul National University Hospital, The University of Western Australia, Sir Charles Gairdner Hospital, Linear Clinical Research, Abramson Cancer Center, University of Pennsylvania, Hospital Universitario 12 De Octubre, Samsung Medical Center, Institut Català d'Oncologia, Duran i Reynals Hospital, Cancer Research UK Oxford Centre, AstraZeneca (Canada), AstraZeneca (Sweden), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162552557